Core Insights - Cosmos Health Inc. has initiated a new research and development program utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements [1][2] - The new initiative builds on the proprietary technology developed during the creation of CCX Hydrogel, focusing on plant-based extract-loaded phytosomes to improve absorption, stability, and bioactivity of phytochemicals [2][5] - The company emphasizes a sustainable, solvent-free process for creating phytosomes, aligning with its commitment to environmentally responsible practices [3][5] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures a range of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [6]

Core Viewpoint - Hofseth BioCare ASA ("HBC") is planning a private placement of new shares to raise between approximately NOK 155 million and NOK 181 million, aimed at capitalizing on the growing demand for salmon-derived nutrition and expanding its market presence [2][3]. Group 1: Private Placement Details - The private placement will consist of between 86,096,132 and 100,638,889 new shares at a fixed price of NOK 1.80 per share [2]. - Pre-commitments totaling approximately NOK 155 million have already been secured, with NOK 103.4 million in cash and NOK 52 million from debt conversion [2][7]. - The placement will be divided into two tranches, with Tranche 1 consisting of up to 68,555,556 shares and Tranche 2 up to 32,083,333 shares [8]. Group 2: Strategic Use of Proceeds - Proceeds will be allocated to expand the B2B ingredients unit and enhance customer adoption of nutraceutical offerings, particularly in high-growth regions like Asia and the US [3]. - Funds will support initiatives in metabolic health and healthy aging, following recent product successes and increased market interest [4]. - Investment will also focus on scaling the Brilliant Petcare brand, which is experiencing global growth in the premium pet nutrition segment [4]. Group 3: Partnerships and R&D - HBC aims to develop new concepts with global distributor partners and strengthen alliances with contract manufacturers, alongside general corporate purposes and marketing activities [5]. - The company will also allocate funds for further research and development to support its innovation pipeline [5]. Group 4: Divestment and Shareholding - In conjunction with the private placement, HBC will divest shares in AecorBio Inc. for approximately USD 5 million, reflecting a 20% valuation increase from the last funding round [6]. - Post-divestment, HBC will retain approximately 52% ownership in AecorBio [6]. Group 5: Regulatory and Application Process - The application period for the private placement starts on October 24, 2025, and is expected to close by October 27, 2025 [11]. - The completion of the private placement is subject to various conditions, including board resolutions and registration of share capital increases [12][13]. - An extraordinary general meeting (EGM) is expected to be convened around November 20, 2025, to approve the issuance of shares in Tranche 2 [15].

Core Insights - A major private-label win has been awarded to a leading direct-to-consumer seller of high-quality natural nutritional supplements for women, indicating strong market demand and competitive positioning in the industry [1] Group 1 - The awarded product consists of specially formulated gummies designed to naturally support a woman's hormonal balance and overall health and well-being, highlighting a focus on women's health in product development [1]

Core Insights - Pangea Natural Foods Inc. announces a strategic collaboration with Dr. Neal Davies and Dr. Raimar Loebenberg to enhance non-injectable peptide delivery systems for consumer wellness applications [1][5] Group 1: Collaboration Details - Amino Innovations, a subsidiary of Pangea, will leverage the expertise of two renowned pharmaceutical scientists to accelerate research and development [1][2] - The collaboration will utilize the University of Alberta's Drug Development and Innovation Centre for formulation and validation [2] Group 2: Research Scope - The partnership aims to establish benchmarks for precision peptide delivery across various formulations, including oral, dermal, and topical [3] - Research will focus on the absorption, bioavailability, and stability of peptides like BPC-157, GHK-Cu, and KPV, using natural enhancers [3][4] Group 3: Strategic Goals - The data generated will enhance Amino Innovations' intellectual property portfolio and regulatory credibility, facilitating new product development in nutraceutical and cosmeceutical markets [4] - The collaboration is expected to create scientific transparency in the wellness industry by generating pharmacokinetic and permeability data [5][6]

Group 1: Company Performance - RF Acquisition Corp II Right (NASDAQ:RFAIR) experienced a significant stock price drop of 33.33% to $0.12, attributed to investor skepticism regarding future prospects and broader market trends affecting speculative investments [1][7] - Electra Battery Materials Corporation (NASDAQ:ELBM) saw a decline of 32.91%, with its stock price falling to $4.71, potentially influenced by disruptions from the Canada Post strike and fluctuations in the electric vehicle market [2][7] - Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS) reported a decrease of 32.06% to $0.69, reflecting changes in company direction, Chinese regulatory policies, and shifts in consumer demand within the health and wellness sector [3][7] - Sunshine Biopharma, Inc. (NASDAQ:SBFMW) faced a decline of 31.67%, with its stock price dropping to $0.23, possibly influenced by updates on drug development and regulatory approvals [4] - OneMedNet Corporation (NASDAQ:ONMDW) saw a decrease of 25.09% to $0.15, facing challenges related to market adoption and competition in the AI healthcare space [5] Group 2: Market Trends and Influences - The stock movements highlight the volatility across various sectors, including technology, healthcare, renewable energy, and consumer goods, indicating diverse factors influencing company performance [6]

Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demandLAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling ...

Core Insights - Cosmos Health Inc. has entered into an exclusive distribution agreement with Diyar United for its Sky Premium Life® nutraceuticals in Kuwait, marking a strategic expansion into the Middle Eastern market [1][2][6] - The agreement grants Diyar United exclusive rights for the registration, promotion, logistics, and distribution of various food supplements, including collagen, vitamins, and herbal blends [3][4] - The initial purchase order exceeds 65,000 units, indicating strong demand and a growing sales pipeline in Kuwait [4] Market Opportunity - Kuwait's nutritional supplements market was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030, growing at a CAGR of around 6.3%, presenting a significant opportunity for Cosmos Health [5] - The partnership with Diyar United, a respected distributor with extensive healthcare experience, is expected to enhance Cosmos Health's market penetration in Kuwait [2][6] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life® [7] - The company operates under European Good Manufacturing Practices (GMP) and is involved in the manufacturing and distribution of pharmaceuticals, food supplements, and medical devices across Europe, Asia, and North America [7] - Cosmos Health is also engaged in R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [7]

Core Insights - Cosmos Health Inc. is at a pivotal moment, having refined its strategy and operations to foster sustainable growth and long-term value creation [1][3] - The company aims to create a global healthcare platform integrating various sectors, including pharmaceuticals, nutraceuticals, and digital finance [4][5] - The ambition for 2030 is to transform into a global powerhouse by scaling branded products and leveraging AI and blockchain technologies [6][7] Vision & Ambition - The company has aligned all business units towards a common goal of making high-quality healthcare accessible globally [4][5] - Cosmos Health emphasizes resilience, creativity, and leadership in rapidly evolving industries [5] Milestones & Achievements - Significant progress has been made in financing, manufacturing capabilities, and innovation pipeline, including securing a $300 million financing facility [9][11] - The company has expanded its manufacturing footprint and strengthened its wholesale operations [10][18] Financial Performance & Outlook - In 2024, Cosmos Health reported revenues of approximately $54.43 million, a 2% increase from 2023, with a notable reduction in operating expenses [40][41] - The company aims for continued growth and profitability, targeting approximately $155.8 million in revenue by 2027 [48][44] Strategy & Roadmap - The growth strategy is built on six pillars, focusing on profitability, cash flow, and scaling high-margin businesses [46] - The company is committed to maintaining financial strength while pursuing innovation and global expansion [49][52] R&D and Innovation - Cosmos Health is advancing its proprietary obesity treatment, CCX0722, and expanding its R&D pipeline across multiple therapeutic areas [25][30] - The company utilizes its AI-enabled platform, Cloudscreen, to enhance drug discovery and accelerate innovation [26][50] Global Expansion - The flagship brand, Sky Premium Life, is expanding internationally, with over 150 premium products and strong demand across various regions [18][19] - The company has established a dual manufacturing hub in the U.S. and Europe to enhance supply chain resilience [18][22] Insider Commitment - The CEO has invested over $18 million of personal capital into the company, demonstrating a strong alignment of interests with shareholders [34][35] Sustainability Commitment - Cosmos Health is focused on balancing growth with social responsibility, emphasizing innovation, market development, and digital asset strategies [53][54]

Core Insights - The demand for health and preventive care products is significantly increasing in Asia and globally, presenting both opportunities and challenges for the industry [3] - Mom's Garden showcased its "0 laxative" gut health solutions at the Vitafoods Asia 2025, attracting attention from international clients and industry partners [1][3] Industry Overview - The Vitafoods Asia serves as a crucial international platform for Asia-Pacific enterprises to grasp trends and connect resources amidst rising international competition, high R&D costs, and regulatory compliance challenges [3] - The event highlighted the growing market for health products, with a focus on innovative solutions that cater to regional consumer needs [3] Company Highlights - Mom's Garden, established in 2002, emphasizes "scientific nutrition, natural power" and focuses on gut health and bone care, aiming to provide natural, safe, and long-lasting dietary solutions [8] - The brand has achieved significant success in the European and American markets and entered the Asia-Pacific market in 2020, adapting to local dietary habits and cultural preferences [8] - The company plans to deepen its localized product strategy in the Asia-Pacific market, leveraging scientific evidence to develop safe and effective nutritional products tailored to regional consumer characteristics [8] Product Innovations - Mom's Garden's key products, including Baicao Garden Qingqing Tablets and Baicao Garden AKK Probiotics, utilize a targeted release system to address constipation and gut microbiome imbalances [5][6] - The "0 laxative" approach is designed to meet the demand for gentle and long-lasting solutions, contrasting with traditional gut health products that rely on stimulants [5][6]

Core Viewpoint - Cosmos Health Inc. has officially launched its U.S. operations with the introduction of its proprietary Sky Premium Life food supplements brand, marking a significant milestone in its expansion strategy into the world's largest nutraceuticals market [1][7]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [8]. - The company operates through subsidiaries in Europe and North America, focusing on manufacturing pharmaceuticals, food supplements, cosmetics, and medical devices [8]. Product Launch and Sales - The Sky Premium Life NOOR Collagen product, formulated with premium marine collagen tripeptide, is now available in the U.S. and is designed to support skin and joint health [3][5]. - Early sales momentum for NOOR Collagen is encouraging, with projections indicating it could generate over $12 million in annualized revenue [5][7]. Market Potential - The U.S. nutraceuticals market was valued at $163.7 billion in 2024 and is expected to grow at a CAGR of 6.2% through 2030, driven by increasing health awareness and demand for natural wellness solutions [6]. - The company anticipates strong gross margins of approximately 75% from its U.S. operations, indicating significant cash flow generation potential [5]. Strategic Commitment - Cosmos Health emphasizes its commitment to regulatory excellence and product integrity by manufacturing all Sky Premium Life products in GMP-certified, FDA-registered U.S. facilities [2]. - The launch of NOOR Collagen is the first step in a series of planned product introductions aimed at meeting strong consumer demand in the U.S. market [8].